You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 12, December 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE 39TH ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, WASHINGTON, DC, MAY 12 TO MAY 14, 1986-PART II
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Intraoperative Probe-Directed Immunodetection Using a Monoclonal Antibody

Patrick J. O'Dwyer, MD; Cathy M. Mojzisik, RN, MS; George H. Hinkle, RPh, MS; Michel Rousseau; John Olsen, MD; Steven E. Tuttle, MD; Rolf F. Barth, PhD; Marlin O. Thurston, PhD; Daniel P. McCabe, MD; William B. Farrar, MD; Edward W. Martin, Jr, MD

Arch Surg. 1986;121(12):1391-1394.


Abstract

• To assess monoclonal antibody (MAb) 17-1A and its F(ab')2 fragment in intraoperative radioimmunodetection and to evaluate further the clinical usefulness of a hand-held gamma-detecting probe (GDP), we injected radiolabeled monoclonal antibody 17-1A three to six days preoperatively or its F(ab')2 fragment two to three days preoperatively into 18 patients with colorectal cancer. Intraoperative GDP counts with tumor-tissue ratios of 1.5:1 or greater were obtained from 15 (75%) of 20 tumor sites, with ratios averaging 2.3:1 for fragments and 3.4:1 for whole antibody. The GDP counts contributed to intraoperative decision making in three patients, either by localization of tumor not identified by inspection or palpation or by mapping margins of resection with histologic confirmation of a local/regional recurrence. These preliminary data demonstrate that probe-directed, intraoperative radioimmunodetection can assist the surgeon in detecting subclinical tumor deposits and thus better evaluate the extent of primary or recurrent colorectal cancers intraoperatively.

(Arch Surg 1986;121:1391-1394)



Author Affiliations

From the Division of Surgical Oncology, the Department of Surgery (Drs O'Dwyer, McCabe, Farrar, and Martin, Mr Rousseau, and Ms Mojzisik), the Department of Pathology (Drs Tuttle and Barth), the Department of Electrical Engineering (Dr Thurston), and the Department of Nuclear Medicine (Messers Hinkle and Rousseau and Dr Olsen), Ohio State University College of Medicine, Columbus.


Footnotes

Accepted for publication Aug 13, 1986.

Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 14, 1986.

Reprint requests to Division of Surgical Oncology, Ohio State University Hospitals, 410 W Tenth Ave, Columbus, OH 43210-1228 (Dr Martin).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Radioimmunoguided Surgery Using Iodine 125 B72.3 in Patients With Colorectal Cancer
Cohen et al.
Arch Surg 1991;126:349-352.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.